HKSE:9606
Duality Biotherapeutics, Inc. · HKSE · Healthcare · HKD · FY for 2025
Figures on this page computed 2026-11-08 13:44 UTC
Last close
n/aHKD
Market data
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-136.5%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
9.8%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
Growth is the furthest below its sector's middle: 0.13 against 0.46 on the market's range.
- Growth-140.6%13 of 100, below its sector
- Returns on capital-104.2%10 of 100, below its sector
- Margins31.1%37 of 100, above its sector
- Price2.4x37 of 100, below its sector
- Safety3.6159 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Then and now
lens 3 of 9| Fact | 2022 | 2025 | Change |
|---|---|---|---|
| Sales | 1,600,000 | 1,851,735,000 | +115,633% |
| Profit | -387,090,000 | -2,527,670,000 | -553% |
| Free cash flow | -321,670,000 | 180,858,000 | +156% |
| Debt | 4,665,000 | 149,775,000 | +3,111% |
| Shares in issue | 83,175,764 | 65,156,000 | -21.7% |
The same five facts for 2022 and 2025, each read from the year's own filing.
The same five facts for 2022 and 2025, each read from the year's own filing.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2022
Sales, 20221,600,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2022
- Reported in
- CNY
Sales, 20251,851,735,000Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Profit, 2022-387,090,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2022
- Reported in
- CNY
Profit, 2025-2,527,670,000Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Free cash flow, 2022-321,670,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2022
- Reported in
- CNY
Free cash flow, 2025180,858,000Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Debt, 20224,665,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2022
- Reported in
- CNY
Debt, 2025149,775,000Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Shares in issue, 202283,175,764
- Source
- computed
- Statement
- income
- Fiscal year
- 2022
- Reported in
- CNY
Shares in issue, 202565,156,000Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY